Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk - Concepedia

Concepedia

Publication | Open Access

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk

DOI Full Paper Access

436

Citations

30

References

2013

Year

Amit Khera, Brendan M. Everett, Michael P. Caulfield, Feras Hantash, Jay G. Wohlgemuth, Paul M. Ridker, Samia Mora

Abstract

http://www.clinicaltrials.gov. Unique identifier: NCT00239681.

References

	Year	Citations
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, New England Journal of Medicine	2008	6.5K
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, Obstetrical & Gynecological Survey Vascular DiseaseElevated C-reactive ProteinUnstable AnginaHyperlipidemiaPharmacotherapy	2009	3.7K
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy New England Journal of Medicine	2011	2.9K
Lipoprotein(a) as a cardiovascular risk factor: current status Børge G. Nordestgaard, M. John Chapman, Kausik K. Ray, European Heart Journal	2010	1.7K
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease Robert Clarke, John F. Peden, Jemma C. Hopewell, New England Journal of Medicine	2009	1.6K
A NEW SERUM TYPE SYSTEM IN MAN—THE L<sub>p</sub> SYSTEM Kåre Berg Acta Pathologica Microbiologica Scandinavica Human MetabolismPhysiologyOrgan PhysiologyHealth Sciences	1963	1.3K
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction Pia R. Kamstrup JAMA	2009	1.3K
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, The Lancet Jupiter TrialCardiovascular DiseaseHyperlipidemiaLdl CholesterolDyslipidemia	2009	1K
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease Christopher P. Cannon, Sukrut Shah, Hayes M. Dansky, New England Journal of Medicine	2010	746
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol Evan A. Stein, Scott Mellis, George D. Yancopoulos, New England Journal of Medicine	2012	659

Page 1